Literature DB >> 46154

Acute lymphoblastic leukaemia: a heterogenous disease.

D G Haegert, J Stuart, J L Smith.   

Abstract

By using several techniques to detect surface markers on T and B lymphocytes, 11 cases of acute lymphoblastic leukaemia (A.L.L.) were studied. In four cases an insignificant number of markers were detected on the lymphoblast populations. In one case a significant number of blasts formed both sheep red blood cell rosettes and Fc rosettes, suggesting a T-cell origin for the neoplastic cells, and in another case the presence of Fc and C3 receptors on the lymphoblast population indicated a B-cell origin. In a further five cases 14-43% of the blasts had detectable surface immunoglobulin. It is concluded that A.L.L. is a heterogeneous disorder, some cases failing to express surface markers and others having either a T-or a B-lymphocyte origin or both.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46154      PMCID: PMC1672505          DOI: 10.1136/bmj.1.5953.312

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  14 in total

1.  T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia.

Authors:  D Belpomme; D Dantchev; E Du Rusquec; D Grandjon; R Huchet; P Pouillart; L Schwarzenberg; J L Amiel; G Mathé
Journal:  Biomedicine       Date:  1974-03

2.  Opsonic adherence of sensitized ox red cells to human lymphocytes as measured by rosette formation.

Authors:  T Hallberg; B W Gurner; R R Coombs
Journal:  Int Arch Allergy Appl Immunol       Date:  1973

3.  B- and T-lymphocyte markers on transformed lymphocytes from mitogen-stimulated cultures of normal and CLL lymphocytes and on tonsil blasts.

Authors:  J L Smith; D Haegert
Journal:  Clin Exp Immunol       Date:  1974-08       Impact factor: 4.330

4.  T and B lymphocytes: striking differences in surface membranes.

Authors:  J N Mehrishi; K Zeiller
Journal:  Br Med J       Date:  1974-03-02

5.  T cell surface markers on lymphoblasts from acute lymphocytic leukemia.

Authors:  L Borella; L Sen
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

6.  Evidence for individual human peripheral blood lymphocytes bearing both B and T cell markers.

Authors:  H B Dickler; N F Adkinson; W D Terry
Journal:  Nature       Date:  1974-01-25       Impact factor: 49.962

7.  The effects of papain, trypsin and phospholipase A on rosette formation.

Authors:  H M Chapel
Journal:  Transplantation       Date:  1973-03       Impact factor: 4.939

8.  B and T lymphocyte subpopulations in human peripheral blood.

Authors:  D G Haegert; T Hallberg; R R Coombs
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

9.  Surface bound immunoglobulins as a cell marker in human lymphoproliferative diseases.

Authors:  J L Preud'homme; M Seligmann
Journal:  Blood       Date:  1972-12       Impact factor: 22.113

10.  Acute lymphoblastic leukemic cells with T (thymus-derived) lymphocyte markers.

Authors:  J H Kersey; A Sabad; K Gajl-Peczalska; H M Hallgren; E J Yunis; M E Nesbit
Journal:  Science       Date:  1973-12-28       Impact factor: 47.728

View more
  4 in total

Review 1.  Polytherapy and Targeted Cancer Drug Resistance.

Authors:  Nilanjana Chatterjee; Trever G Bivona
Journal:  Trends Cancer       Date:  2019-02-26

2.  Prognosis and treatment of acute lymphoblastic leukemia. Study of 650 patients.

Authors:  C Jacquillat; M Weil; M F Auclerc; C Chastang; G Flandrin; V Izrael; G Schaison; L Degos; M Boiron; J Bernard
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  T-cell and B-cell identification in the diagnosis of lymphoproliferative disease. A review.

Authors:  T L Whiteside; D T Rowlands
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

4.  Surface membrane determinants on childhood acute lymphocytic leukemia cells: immunoglobulin, Fc and C3 receptors.

Authors:  E C Esber; N Movassaghi; S L Leikin
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.